Intravenous immunoglobulin in the management of lupus nephritis

Autoimmune Diseases

Volumn 1, Issue 1, 2012, Pages

  Wenderfer, Scott E ^a   Thacker, Trisha ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FC RECEPTOR; IMMUNOGLOBULIN; PREDNISONE; ACETYLSALICYLIC ACID; HEPARIN; METHYLPREDNISOLONE;

CHILL; COMORBIDITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HEADACHE; HUMAN; KIDNEY PARENCHYMA; LIMB PAIN; LUNG EMBOLISM; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; NAUSEA; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; RISK BENEFIT ANALYSIS; SALVAGE THERAPY; SEIZURE; SYSTEMIC LUPUS ERYTHEMATOSUS; VISUAL DISORDER; VOMITING; ALOPECIA; ANTIBODY TITER; ASEPTIC MENINGITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; DERMATITIS; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; HEPATITIS; HYPONATREMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; KIDNEY BIOPSY; KIDNEY FAILURE; LOW DRUG DOSE; MEDLINE; NEPHROTOXICITY; NEUTROPENIA; PLASMAPHERESIS; VASCULITIS;

EID: 84874926636     PISSN: None     EISSN: 20900430     Source Type: Journal    
DOI: 10.1155/2012/589359     Document Type: Review

References (113)

1. Nimmerjahn F., Ravetch J. V., The antiinflammatory activity of IgG: the intravenous IgG paradox. The Journal of Experimental Medicine 2007 204 1 11 15 2-s2.0-33846423857 10.1084/jem.20061788 (Pubitemid 46148750)
2. Rauova L., Lukac J., Levy Y., Rovensky J., Shoenfeld Y., High-dose intravenous immunoglobulins for lupus nephritisa salvage immunomodulation. Lupus 2001 10 3 209 213 2-s2.0-0035051221 10.1191/096120301668222237 (Pubitemid 32410079)
3. Toubi E., Kessel A., Shoenfeld Y., High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Human Immunology 2005 66 4 395 402 2-s2.0-18144421198 10.1016/j.humimm.2005.01.022 (Pubitemid 40615795)
4. Zandman-Goddard G., Levy Y., Shoenfeld Y., Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clinical Reviews in Allergy and Immunology 2005 29 3 219 228 2-s2.0-29944437185 10.1385/CRIAI:29:3:219 (Pubitemid 43041673)
5. Bayry J., Negi V. S., Kaveri S. V., Intravenous immunoglobulin therapy in rheumatic diseases. Nature Reviews Rheumatology 2011 7 6 349 359 2-s2.0-79958140473 10.1038/nrrheum.2011.61
6. Samuelsson A., Towers T. L., Ravetch J. V., Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001 291 5503 484 486 2-s2.0-0035910392 10.1126/science.291.5503.484 (Pubitemid 32097072)
7. Clynes R., Protective mechanisms of IVIG. Current Opinion in Immunology 2007 19 6 646 651 2-s2.0-36849050907 10.1016/j.coi.2007.09.004 (Pubitemid 350236813)
8. Nimmerjahn F., Ravetch J. V., Anti-inflammatory actions of intravenous immunoglobulin. Annual Review of Immunology 2008 26 513 533 2-s2.0-42649089750 10.1146/annurev.immunol.26.021607.090232 (Pubitemid 351600384)
9. van Mirre E., Teeling J. L., van der Meer J. W. M., Bleeker W. K., Hack C. E., Monomeric IgG in intravenous Ig preparations is a functional antagonist of Fc γ RII and Fc γ RIIIb. Journal of Immunology 2004 173 1 332 339 2-s2.0-2942746505 (Pubitemid 38797358)
10. Lutz H. U., Stammler P., Bianchi V., Trüeb R. M., Hunziker T., Burger R., Jelezarova E., Späth P. J., Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 2004 103 2 465 472 2-s2.0-0942276857 10.1182/blood-2003-05-1530 (Pubitemid 38140074)
11. Boruchov A. M., Heller G., Veri M. C., Bonvini E., Ravetch J. V., Young J. W., Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. The Journal of Clinical Investigation 2005 115 10 2914 2923 2-s2.0-26444577543 10.1172/JCI24772 (Pubitemid 41434419)
12. Konrad S., Baumann U., Schmidt R. E., Gessner J. E., Intravenous immunoglobulin (IVIG)-mediated neutralisation of C5a: a direct mechanism of IVIG in the maintenance of a high Fc γ RIIB to Fc γ RIII expression ratio on macrophages. British Journal of Haematology 2006 134 3 345 347 2-s2.0-33745624817 10.1111/j.1365-2141.2006.06185.x (Pubitemid 43990803)
13. Benacerraf B., Sebestyen M., Cooper N. S., The clearance of antigen antibody complexes from the blood by the reticuloendothelial system. Journal of Immunology 1959 82 2 131 137 2-s2.0-0000450389
14. Edberg J. C., Kujala G. A., Taylor R. P., Rapid immune adherence reactivity of nascent, soluble antibody/DNA immune complexes in the circulation. Journal of Immunology 1987 139 4 1240 1244 2-s2.0-0023257926 (Pubitemid 17125066)
15. Schifferli J. A., Taylor R. P., Physiological and pathological aspects of circulating immune complexes. Kidney International 1989 35 4 993 1003 2-s2.0-0024542522 (Pubitemid 19099713)
16. H2 pathway. Nature 2011 475 7354 110 113 2-s2.0-79960046406 10.1038/nature10134
17. Abonia J. P., Friend D. S., Austen W. G., Moore F. D., Carroll M. C., Chan R., Afnan J., Humbles A., Gerard C., Knight P., Kanaoka Y., Yasuda S., Morokawa N., Austen K. F., Stevens R. L., Gurish M. F., Mast cell protease 5 mediates ischemia-reperfusion injury of mouse skeletal muscle. Journal of Immunology 2005 174 11 7285 7291 2-s2.0-21044433149 (Pubitemid 40705698)
18. Le Pottier L., Sapir T., Bendaoud B., Youinou P., Shoenfeld Y., Pers J. O., Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Annals of the New York Academy of Sciences 2007 1110 426 432 2-s2.0-35748972064 10.1196/annals.1423.044 (Pubitemid 350043031)
19. Orange J. S., Hossny E. M., Weiler C. R., Ballow M., Berger M., Bonilla F. A., Buckley R., Chinen J., El-Gamal Y., Mazer B. D., Nelson R. P., Patel D. D., Secord E., Sorensen R. U., Wasserman R. L., Cunningham-Rundles C., Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Journal of Allergy and Clinical Immunology 2006 117 4, supplement S525 S553 2-s2.0-33645341439 10.1016/j.jaci.2006.01.015
20. Kaneko Y., Nimmerjahn F., Ravetch J. V., Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006 313 5787 670 673 2-s2.0-33746888249 10.1126/science.1129594 (Pubitemid 44201145)
21. Andrew Moore R., Derry S., Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Research and Therapy 2006 8, article R182 2-s2.0-33847193118 10.1186/ar2093
22. Fiore E., Rizzi M., Ragazzi M., Vanoni F., Bernasconi M., Bianchetti M. G., Simonetti G. D., Acute hemorrhagic edema of young children (cockade purpura and edema): a case series and systematic review. Journal of the American Academy of Dermatology 2008 59 4 684 695 2-s2.0-51349086253 10.1016/j.jaad.2008.06.005
23. Ramos-Casals M., Soto M. J., Cuadrado M. J., Khamashta M. A., Rituximab in systemic lupus erythematosus A systematic review of off-label use in 188 cases. Lupus 2009 18 9 767 776 2-s2.0-67650606765 10.1177/0961203309106174
24. Esdaile J. M., Joseph L., Mackenzie T., Kashgarian M., Hayslett J. P., The benefit of early treatment with immunosuppressive agents in lupus nephritis. The Journal of Rheumatology 1994 21 11 2046 2051 2-s2.0-0028077128 (Pubitemid 24352349)
25. Esdaile J. M., Joseph L., MacKenzie T., Kashgarian M., Hayslett J. P., The benefit of early treatment with immunosuppressive drugs in lupus nephritis. The Journal of Rheumatology 1995 22 6, article 1211 2-s2.0-0029072583
26. Ballow M., Parke A., The uses of intravenous immune globulin in collagen vascular disorders. The Journal of Allergy and Clinical Immunology 1989 84 4 608 612 2-s2.0-45349109535
27. Schroeder J. O., Zeuner R. A., Euler H. H., Löffler H., High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. The Journal of Rheumatology 1996 23 1 71 75 2-s2.0-0030068117 (Pubitemid 26037213)
28. Sherer Y., Kuechler S., Scali J. J., Rovensky J., Levy Y., Zandman-Goddard G., Shoenfeld Y., Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Israel Medical Association Journal 2008 10 1 55 57 2-s2.0-41149157478 (Pubitemid 351649467)
29. Hjortkjaer Petersen H., Nielsen H., Hansen M., Stensgaard-Hansen F., Helin P., High-dose immunoglobulin therapy in pericarditis caused by SLE. Scandinavian The Journal of Rheumatology 1990 19 1 91 93 2-s2.0-0025021994 (Pubitemid 20062490)
30. Maier W. P., Gordon D. S., Howard R. F., Saleh M. N., Miller S. B., Lieberman J. D., Woodlee P. M., Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis and Rheumatism 1990 33 8 1233 1239 2-s2.0-0025103006 (Pubitemid 20273312)
31. Tomer Y., Shoenfeld Y., Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clinical and Experimental Rheumatology 1992 10 4 391 393 2-s2.0-0026702958
32. Lesprit P., Mouloud F., Bierling P., Schaeffer A., Cesaro P., Brun-Buisson C., Godeau B., Prolonged remission of SLE-associated polyradiculoneuropathy after a single course of intravenous immunoglobulin. Scandinavian The Journal of Rheumatology 1996 25 3 177 179 2-s2.0-0029895373 (Pubitemid 26180280)
33. Aharon A., Levy Y., Bar-Dayan Y., Afek A., Zandman-Goddard G., Skurnik Y., Fabrrizzi F., Shoenfeld Y., Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 1997 6 4 408 411 2-s2.0-0030958502 (Pubitemid 27232138)
34. Généreau T., Chosidow O., Danel C., Chérin P., Herson S., High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Archives of Dermatology 1999 135 9 1124 1125 2-s2.0-0344850203 10.1001/archderm.135.9.1124 (Pubitemid 29430512)
35. Sherer Y., Levy Y., Langevitz P., Lorber M., Fabrizzi F., Shoenfeld Y., Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clinical Rheumatology 1999 18 2 170 173 2-s2.0-0032903777 10.1007/s100670050079 (Pubitemid 29223043)
36. Sherer Y., Levy Y., Shoenfeld Y., Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clinical Rheumatology 1999 18 3 238 240 2-s2.0-0032983315 10.1007/s100670050091 (Pubitemid 29284723)
37. Meissner M., Sherer Y., Levy Y., Chwalinska-Sadowska H., Langevitz P., Shoenfeld Y., Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis. Rheumatology International 2000 19 5 199 201 2-s2.0-0033898237 (Pubitemid 30598871)
38. Sherer Y., Levy Y., Shoenfeld Y., Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology 2000 39 4 421 426 2-s2.0-0034025443 (Pubitemid 30307329)
39. Hoshi K. I., Matsuda M., Ishikawa M., Mitsuhashi S., Gono T., Hashimoto T., Ikeda S. I., Successful treatment of fulminant pulmonary hemorrhage associated with systemic lupus erythematosus. Clinical Rheumatology 2004 23 3 252 255 2-s2.0-3042539335 10.1007/s10067-003-0859-2 (Pubitemid 38812208)
40. De Pità O., Bellucci A. M., Ruffelli M., Girardelli C. R., Puddu P., Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus 1997 6 4 415 417 2-s2.0-0030919040
41. Gomard-Mennesson E., Ruivard M., Koenig M., Woods A., Magy N., Ninet J., Rousset H., Salles G., Broussolle C., Sève P., Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 Cases. Lupus 2006 15 4 223 231 2-s2.0-33646249960 10.1191/0961203306lu2292oa
42. Arnal C., Piett J. C., Léone J., Taillan B., Hachulla E., Roudot-Thoraval F., Papo T., Schaeffer A., Bierling P., Godeau B., Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 Cases. The Journal of Rheumatology 2002 29 1 75 83 2-s2.0-0036140369 (Pubitemid 34041862)
43. Branch D. W., Peaceman A. M., Druzin M., Silver R. K., El-Sayed Y., Silver R. M., Esplin M. S., Spinnato J., Harger J., A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. American Journal of Obstetrics and Gynecology 2000 182 1 122 127 2-s2.0-0033979270 (Pubitemid 30074379)
44. Vaquero E., Lazzarin N., Valensise H., Menghini S., Di Pierro G., Cesa F., Romanini C., Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin. American Journal of Reproductive Immunology 2001 45 3 174 179 2-s2.0-0035133651 (Pubitemid 32156569)
45. Triolo G., Ferrante A., Ciccia F., Accardo-Palumbo A., Perino A., Castelli A., Giarratano A., Licata G., Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis and Rheumatism 2003 48 3 728 731 2-s2.0-0037334440 10.1002/art.10957 (Pubitemid 36302009)
46. Levy Y., Sherer Y., Ahmed A., Langevitz P., George J., Fabbrizzi F., Terryberry J., Meissner M., Lorber M., Peter J. B., Shoenfeld Y., A study of 20 SLE patients with intravenous immunoglobulinclinical and serologic response. Lupus 1999 8 9 705 712 2-s2.0-0032728801
47. Zandman-Goddard G., Krauthammer A., Levy Y., Langevitz P., Shoenfeld Y., Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clinical Reviews in Allergy and Immunology 2012 42 2 247 255 10.1007/s12016-011-8278-7 2-s2.0-79959806758 10.1007/s12016-011-8278-7
48. Akashi K., Nagasawa K., Mayumi T., Yokota E., Oochi N., Kusaba T., Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. The Journal of Rheumatology 1990 17 3 375 379 2-s2.0-0025232853 (Pubitemid 20106618)
49. Oliet A., Hernandez E., Gallar P., Vigil A., High-dose intravenous gamma-globulin in systemic lupus erythematosus. Nephron 1992 62 4, article 465 2-s2.0-0026493874
50. Winder A., Molad Y., Ostfeld I., Kenet G., Pinkhas J., Sidi Y., Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. The Journal of Rheumatology 1993 20 3 495 498 2-s2.0-0027522476 (Pubitemid 23102474)
51. Arahata H., Migita K., Izumoto H., Miyashita T., Munakata H., Nakamura H., Tominaga M., Origuchi T., Kawabe Y., Hida A., Taguchi T., Eguchi K., Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intravenous immunoglobulins. Clinical Rheumatology 1999 18 1 77 81 2-s2.0-0033005725 10.1007/s100670050060 (Pubitemid 29104763)
52. Viertel A., Weidmann E., Wigand R., Geiger H., Mondorf U. F., Treatment of severe systemic lupus erythematosus with immunoadsorption and intravenous immunoglobulins. Intensive Care Medicine 2000 26 6 823 824 2-s2.0-0033948581 (Pubitemid 30449687)
53. Gan H. C., Hyoon K., Fong K. Y., Clinical outcomes of patients with biopsy-proven lupus nephritis in NUH. Singapore Medical Journal 2002 43 12 614 616 2-s2.0-0036928526 (Pubitemid 36307077)
54. Kamali S., Cefle A., Sayarlioglu M., Gul A., Inanc M., Ocal L., Aral O., Konice M., Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. Rheumatology International 2005 25 3 211 214 2-s2.0-17744388323 10.1007/s00296-003-0422-0 (Pubitemid 40576788)
55. Micheloud D., Nuño L., Rodríguez-Mahou M., Sánchez-Ramón S., Ortega M. C., Aguarón A., Junco E., Carbone J., Fernández-Cruz E., Carreño L., López-Longo F. J., Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy. Lupus 2006 15 12 881 885 2-s2.0-33845968087 10.1177/0961203306070970 (Pubitemid 46044921)
56. Levy Y., Sherer Y., George J., Rovensky J., Lukac J., Rauova L., Poprac P., Langevitz P., Fabbrizzi F., Shoenfeld Y., Intravenous immunoglobulin treatment of lupus nephritis. Seminars in Arthritis and Rheumatism 2000 29 5 321 327 2-s2.0-0034098474 (Pubitemid 30235983)
57. Francioni C., Galeazzi M., Fioravanti A., Gelli R., Megale F., Marcolongo R., Long term I.V. Ig treatment in systemic lupus erythematosus. Clinical and Experimental Rheumatology 1994 12 2 163 168 2-s2.0-0028322128 (Pubitemid 24159181)
58. Monova D., Belovezhdov N., Altunkova I., Monov S., Intravenous immunoglobulin G in the treatment of patients with chronic glomerulonephritis: clinical experience lasting 15 years. Nephron 2002 90 3 262 266 2-s2.0-0036190804 10.1159/000049061 (Pubitemid 34195752)
59. Bridoux F., Vrtovsnik F., Noël C., Saunier P., Mougenot B., Lemaitre V., Dracon M., Lelièvre G., Vanhille P., Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival. Nephrology Dialysis Transplantation 1998 13 2 298 304 2-s2.0-0031985882 (Pubitemid 28062188)
60. Becker B. N., Fuchs H., Hakim R., Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease. Journal of the American Society of Nephrology 1995 5 10 1746 1750 2-s2.0-0029039476
61. Lin C. Y., Hsu H. C., Chiang H., Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 1989 53 4 303 310 2-s2.0-0024428968 (Pubitemid 19267243)
62. Welch T. R., McAdams A. J., Beischel L. S., Glomerulonephritis associated with complete deficiency of the fourth component of complement: response to intravenous immunoglobulin. Arthritis and Rheumatism 1995 38 9 1333 1337 2-s2.0-0029157307 10.1002/art.1780380923
63. Silvestris F., D'Amore O., Cafforio P., Savino L., Dammacco F., Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG. Clinical and Experimental Immunology, Supplement 1996 104 supplement 1 91 97 2-s2.0-0029965906
64. Boletis J. N., Ioannidis J. P. A., Boki K. A., Moutsopoulos H. M., Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. The Lancet 1999 354 9178 569 570 2-s2.0-0033554258 10.1016/S0140-6736(99)01575-5 (Pubitemid 29381378)
65. Corvetta A., Della Bitta R., Gabrielli A., Spaeth P. J., Danieli G., Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clinical and Experimental Rheumatology 1989 7 3 295 299 2-s2.0-0024392530 (Pubitemid 19200339)
66. Chacko B., John G. T., Balakrishnan N., Kirubakaran M. G., Jacob C. K., Osmotic nephropathy resulting from maltose-based intravenous immunoglobulin therapy. Renal Failure 2006 28 2 193 195 2-s2.0-33645547210 10.1080/ 08860220500531286
67. Tan S., Tambar S., Chohan S., Ramsey-Goldman R., Lee C., Acute myocardial infarction after treatment of thrombocytopenia in a young woman with systemic lupus erythematosus. Journal of Clinical Rheumatology 2008 14 6 350 352 2-s2.0-64149104741 10.1097/RHU.0b013e31817de0fb
68. Ng S. K. B., Intravenous immunoglobulin infusion causing pseudohyponatremia. Lupus 1999 8 6 488 490 2-s2.0-0032832482 (Pubitemid 29423589)
69. Ben-Chetrit E., Putterman C., Grebenau M. D., Transient neutropenia induced by intravenous immune globulin. The New England Journal of Medicine 1991 326 4 270 271 2-s2.0-0026337229
70. Pasatiempo A. M. G., Kroser J. A., Rudnick M., Hoffman B. I., Acute renal failure after intravenous immunoglobulin therapy. The Journal of Rheumatology 1994 21 2 347 349 2-s2.0-0028327765 (Pubitemid 24078852)
71. Barron K. S., Sher M. R., Silverman E. D., Intravenous immunoglobulin therapy: magic or black magic. The Journal of Rheumatology 1992 19 33 94 97 2-s2.0-0026554526
72. Centers for Disease Control and Prevention, Renal insufficiency and failure associated with immune globulin intravenous therapyUnited States, 19851998. Morbidity and Mortality Weekly Report 1999 48 24 518 521
73. Sati H. I. A., Ahya R., Watson H. G., Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy. British Journal of Haematology 2001 113 2 556 557 2-s2.0-0035021571 10.1046/j.1365-2141.2001.02742.x (Pubitemid 32523170)
74. Orbach H., Tishler M., Shoenfeld Y., Intravenous immunoglobulin and the kidneya two-edged sword. Seminars in Arthritis and Rheumatism 2004 34 3 593 601 2-s2.0-10444255401 10.1016/j.semarthrit.2004.06.003 (Pubitemid 39643121)
75. Li N., Zhao M., Hilario-Vargas J., Prisayanh P., Warren S., Diaz L. A., Roopenian D. C., Liu Z., Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. The Journal of Clinical Investigation 2005 115 12 3440 3450 2-s2.0-31044440897 10.1172/JCI24394 (Pubitemid 43121832)
76. Gonzalez-Gay M. A., The pros and cons of intravenous immunoglobulin treatment in autoimmune nephropathy. Seminars in Arthritis and Rheumatism 2004 34 3 573 574 2-s2.0-10444261147 10.1016/j.semarthrit.2004.07.006 (Pubitemid 39643118)
77. Mauer S. M., Fish A. J., Blau E. B., Michael A. F., The glomerular mesangium. I. Kinetic studies of macromolecular uptake in normal and nephrotic rats. The Journal of Clinical Investigation 1972 51 5 1092 1101 2-s2.0-0015334043
78. Mauer S. M., Fish A. J., Day N. K., Michael A. F., The glomerular mesangium. II. Studies of macromolecular uptake in nephrotoxic nephritis in rats. The Journal of Clinical Investigation 1974 53 2 431 439 2-s2.0-0015951366
79. Mauer S. M., Sutherland D. E., Howard R. J., Fish A. J., Najarian J. S., Michael A. F., The glomerular mesangium. 3. Acute immune mesangial injury: a new model of glomerulonephritis. The Journal of Experimental Medicine 1973 137 3 553 570 2-s2.0-0015595489
80. Shvil Y., Michael A. F., Mauer S. M., Uptake of aggregated immunoglobulin by the mouse kidney. I. Effect of endotoxin. British Journal of Experimental Pathology 1980 61 1 22 29 2-s2.0-0018835512 (Pubitemid 10131136)
81. Shvil Y., Mauer S. M., Michael A. F., Uptake of aggregated immunoglobulin by the mouse kidney. II. Effect of hydrocortisone. British Journal of Experimental Pathology 1980 61 1 30 38 2-s2.0-0018843573 (Pubitemid 10131137)
82. Santiago A., Mori T., Satriano J., Schlondorff D., Regulation of Fc receptors for IgG on cultured rat mesangial cells. Kidney International 1991 39 1 87 94 2-s2.0-0025965362
83. Singhal P. C., Santiago A., Satriano J., Hays R. M., Schlondorff D., Effects of vasoactive agents on uptake of immunoglobulin G complexes by mesangial cells. American Journal of Physiology 1990 258 3 F589 F596 2-s2.0-0025308366 (Pubitemid 20103125)
84. Neuwirth R., Singhal P., Diamond B., Hays R. M., Lobmeyer L., Clay K., Schlondorff D., Evidence for immunoglobulin Fc receptor-mediated prostaglandin2 and platelet-activating factor formation by cultured rat mesangial cells. The Journal of Clinical Investigation 1988 82 3 936 944 2-s2.0-0023805930
85. Sedor J. R., Carey S. W., Emancipator S. N., Immune complexes bind to cultured rat glomerular mesangial cells to stimulate superoxide release. Evidence for an Fc receptor. Journal of Immunology 1987 138 11 3751 3757 2-s2.0-0023266398 (Pubitemid 17078246)
86. Herrada A. A., Contreras F. J., Tobar J. A., Pacheco R., Kalergis A. M., Immune complex-induced enhancement of bacterial antigen presentation requires Fc γ Receptor III expression on dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 2007 104 33 13402 13407 2-s2.0-34548093760 10.1073/pnas.0700999104 (Pubitemid 47293957)
87. Ravetch J. V., Bolland S., IgG Fc receptors. Annual Review of Immunology 2001 19 275 290 2-s2.0-0035057022 10.1146/annurev.immunol.19.1.275 (Pubitemid 32368037)
88. Novak N., Kraft S., Bieber T., IgE receptors. Current Opinion in Immunology 2001 13 6 721 726 2-s2.0-0035546052 10.1016/S0952-7915(01)00285-0 (Pubitemid 33000168)
89. Wines B. D., Hogarth P. M., IgA receptors in health and disease. Tissue Antigens 2006 68 2 103 114 2-s2.0-33747195313 10.1111/j.1399-0039.2006.00613.x (Pubitemid 44392318)
90. Gomez-Guerrero C., Lopez-Armada M. J., Gonzalez E., Egido J., Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF- α and IL-6, and proliferation. Journal of Immunology 1994 153 11 5247 5256 2-s2.0-0028172011 (Pubitemid 24356157)
91. Radeke H. H., Janssen-Graalfs I., Sowa E. N., Chouchakova N., Skokowa J., Löscher F., Schmidt R. E., Heeringa P., Engelbert Gessner J., Opposite regulation of type II and III receptors for immunoglobulin G in mouse glomerular mesangial cells and in the induction of anti-glomerular basement membrane (GBM) nephritis. The Journal of Biological Chemistry 2002 277 30 27535 27544 2-s2.0-0037178866 10.1074/jbc.M200419200 (Pubitemid 34951774)
92. Mancilla-Jimenez R., Appay M. D., Bellon B., IgG Fc membrane receptor on normal human glomerular visceral epithelial cells. Virchows Archiv 1984 404 2 139 158 2-s2.0-0021127465 (Pubitemid 14028687)
93. Haakenstad A. O., Striker G. E., Mannik M., The glomerular deposition of soluble immune complexes prepared with reduced and alkylated antibodies and with intact antibodies in mice. Laboratory Investigation 1976 35 3 293 301 2-s2.0-0017167882
94. Mannik M., David K. A., Gauthier V. J., Preparation and characterization of 4-azido-2-nitrophenyl human serum albumin as an antigen for covalent cross-linking of immune complexes. Journal of Immunology 1981 127 5 1993 1999 2-s2.0-0019509644 (Pubitemid 11023185)
95. Gauthier V. J., Mannik M., Striker G. E., Effect of cationized antibodies in preformed immune complexes on deposition and persistence in renal glomeruli. The Journal of Experimental Medicine 1982 156 3 766 777 2-s2.0-0019993738 (Pubitemid 12026986)
96. Mannik M., Agodoa L. Y., David K. A., Rearrangement of immune complexes in glomeruli leads to persistence and development of electron-dense deposits. The Journal of Experimental Medicine 1983 157 5 1516 1528 2-s2.0-0020621387 (Pubitemid 13088994)
97. Haymann J. P., Delarue F., Baud L., Sraer J. D., Aggregated IgG bind to glomerular epithelial cells to stimulate urokinase release through an endocytosis-independent process. Nephron Experimental Nephrology 2004 98 1 e13 e21 2-s2.0-4644268434 10.1159/000079928
98. Fujii H., Nakatani K., Arita N., Ito M. R., Terada M., Miyazaki T., Yoshida M., Ono M., Fujiwara T., Saiga K., Ota T., Ohtani H., Lockwood M., Sasaki T., Nose M., Intenalization of antibodies by endothelial cells via fibronectin implicating a novel mechanism in lupus nephritis. Kidney International 2003 64 5 1662 1670 2-s2.0-0142249404 10.1046/j.1523-1755.2003. 00252.x (Pubitemid 37323694)
99. Frank M. M., Lawley T. J., Hamburger M. I., Brown E. J., Immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases. Annals of Internal Medicine 1983 98 2 206 218 2-s2.0-0020712533 (Pubitemid 13190923)
100. Jennette J. C., Heptinstall R. H., Heptinstall's Pathology of the Kidney 2007 6th Philadelphia, Pa, USA Lippincott Williams & Wilkins
101. Bagheri N., Chintalacharuvu S. R., Emancipator S. N., Proinflammatory cytokines regulate Fc α R expression by human mesangial cells in vitro. Clinical and Experimental Immunology 1997 107 2 404 409 2-s2.0-0031014966 (Pubitemid 27049271)
102. Santiago A., Satriano J., DeCandido S., Holthofer H., Schreiber R., Unkeless J., Schlondorff D., A specific Fc γ receptor on cultured rat mesangial cells. Journal of Immunology 1989 143 8 2575 2582 2-s2.0-0024460593 (Pubitemid 19260067)
103. Morcos M., Hansch G. M., Schonermark M., Ellwanger S., Harle M., Heckl-Ostreicher B., Human glomerular mesangial cells express CD16 and may be stimulated via this receptor. Kidney International 1994 46 6 1627 1634 2-s2.0-0028154753 (Pubitemid 24370478)
104. Radeke H. H., Gessner J. E., Uciechowski P., Magert H. J., Schmidt R. E., Resch K., Intrinsic human glomerular mesangial cells can express receptors for IgG complexes (hFc γ RIII-A) and the associated Fc ε RI γ -chain. Journal of Immunology 1994 153 3 1281 1292 2-s2.0-0028243070
105. Uciechowski P., Schwarz M., Gessner J. E., Schmidt R. E., Resch K., Radeke H. H., IFN-gamma induces the high-affinity Fc receptor I for IgG (CD64) on human glomerular mesangial cells. European Journal of Immunology 1998 28 9 2928 2935 (Pubitemid 28425250)
106. Gomez-Guerrero C., Gonzalez E., Egido J., Evidence for a specific IgA receptor in rat and human mesangial cells. Journal of Immunology 1993 151 12 7172 7181 2-s2.0-0027138746 (Pubitemid 24001091)
107. Suzuki Y., Ra C., Saito K., Horikoshi S., Hasegawa S., Tsuge T., Okumura K., Tomino Y., Expression and physical association of Fc α receptor and Fc receptor γ chain in human mesangial cells. Nephrology Dialysis Transplantation 1999 14 5 1117 1123 2-s2.0-0032893428 10.1093/ndt/14.5.1117 (Pubitemid 29209294)
108. Matre R., Tonder O., Wesenberg F., Human renal glomeruli possess no Fc γ receptors. Clinical Immunology and Immunopathology 1980 17 2 157 162 2-s2.0-0018867490 (Pubitemid 10048597)
109. Haymann J. P., Levraud J. P., Bouet S., Kappes V., Hagège J., Nguyen G., Xu Y., Rondeau E., Sraer J. D., Characterization and localization of the neonatal Fc receptor in adult human kidney. Journal of the American Society of Nephrology 2000 11 4 632 639 2-s2.0-0034023794 (Pubitemid 30171872)
110. Akilesh S., Huber T. B., Wu H., Wang G., Hartleben B., Kopp J. B., Miner J. H., Roopenian D. C., Unanue E. R., Shaw A. S., Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proceedings of the National Academy of Sciences of the United States of America 2008 105 3 967 972 2-s2.0-38949210805 10.1073/pnas.0711515105 (Pubitemid 351282065)
111. Debre M., Bonnet M. C., Fridman W. H., Carosella E., Philippe N., Reinert P., Vilmer E., Kaplan C., Teillaud J. L., Griscelli C., Infusion of Fc γ fragments for treatment of children with acute immune thrombocytopenic purpura. The Lancet 1993 342 8877 945 949 2-s2.0-0027504398 10.1016/0140-6736(93)92000-J (Pubitemid 23305497)
112. Anthony R. M., Nimmerjahn F., Ashline D. J., Reinhold V. N., Paulson J. C., Ravetch J. V., Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008 320 5874 373 376 2-s2.0-42349085035 10.1126/science.1154315 (Pubitemid 351555659)
113. Anthony R. M., Wermeling F., Ravetch J. V., Novel roles for the IgG Fc glycan. Annals of the New York Academy of Sciences 2012 1253 170 180 10.1111/j.1749-6632.2011.06305.x